$159 Million is the total value of Knoll Capital Management, LLC's 41 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 18.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BHVN | Buy | Biohaven Pharmactl Hldg Co L | $106,813,000 | -13.6% | 900,844 | +0.4% | 67.04% | -1.3% |
| ENTX | Entera Bio Ltd | $7,130,000 | +2.0% | 2,484,275 | 0.0% | 4.48% | +16.4% | |
| EIGR | Eiger Biopharmaceuticals Inc | $5,762,000 | +59.9% | 694,232 | 0.0% | 3.62% | +82.6% | |
| ORGS | Orgenesis, Inc. | $4,568,000 | +20.5% | 1,316,364 | 0.0% | 2.87% | +37.6% | |
| ALDX | Aldeyra Therapeutics Inc | $3,376,000 | +11.1% | 759,405 | 0.0% | 2.12% | +27.0% | |
| CRBP | Corbus Pharmaceuticals HLDGS | $2,684,000 | -13.6% | 5,045,870 | 0.0% | 1.68% | -1.3% | |
| AVXL | New | Anavex Life Sciences Corp | $2,595,000 | – | 210,789 | +100.0% | 1.63% | – |
| APLT | Buy | Applied Therapeutics Inc | $2,283,000 | -75.3% | 1,082,123 | +4.8% | 1.43% | -71.8% |
| BX | Sell | Blackstone Group LP | $2,006,000 | -35.4% | 16,000 | -33.3% | 1.26% | -26.2% |
| ANET | Arista Networks Inc | $1,918,000 | -0.4% | 13,800 | 0.0% | 1.20% | +13.8% | |
| CVS | CVS Health Corp | $1,460,000 | -0.2% | 14,500 | 0.0% | 0.92% | +13.9% | |
| TMO | Thermo Fischer Scientific Inc | $1,240,000 | -11.5% | 2,100 | 0.0% | 0.78% | +1.0% | |
| MO | Altria Group Inc | $1,186,000 | +11.5% | 22,700 | 0.0% | 0.74% | +27.2% | |
| BAH | Booz Allen Hamilton HLDG CORcl a | $1,142,000 | +6.6% | 13,000 | 0.0% | 0.72% | +21.7% | |
| LUMN | Lumen Technologies Inc | $1,127,000 | -10.2% | 100,000 | 0.0% | 0.71% | +2.5% | |
| V | Visa | $1,074,000 | +2.2% | 4,850 | 0.0% | 0.67% | +16.6% | |
| GLW | Corning Inc | $982,000 | +1.4% | 26,600 | 0.0% | 0.62% | +15.8% | |
| AEM | Buy | AGNICO EAGLE MINES LTD | $943,000 | +156.9% | 15,393 | +123.1% | 0.59% | +193.1% |
| AMD | Sell | Advanced Micro Devices Inc | $897,000 | -49.5% | 8,200 | -33.6% | 0.56% | -42.4% |
| ASML | ASML Holdings | $855,000 | -15.7% | 1,280 | 0.0% | 0.54% | -3.6% | |
| OSK | OSHKOSH CORP | $850,000 | -8.1% | 8,450 | 0.0% | 0.53% | +4.9% | |
| ALT | Altimmune Inc | $810,000 | -33.5% | 132,978 | 0.0% | 0.51% | -24.1% | |
| ABEO | Abeona Therapeutics Inc | $709,000 | +8.9% | 2,215,740 | 0.0% | 0.44% | +24.3% | |
| OR | OSISKO GOLD ROYALTIES LTD | $612,000 | +5.7% | 190,000 | 0.0% | 0.38% | +20.8% | |
| SPRO | New | Spero Therapeutics Inc | $609,000 | – | 70,000 | +100.0% | 0.38% | – |
| FNV | FRANCO NEV CORP | $598,000 | +15.2% | 3,750 | 0.0% | 0.38% | +31.6% | |
| SA | SEABRIDGE GOLD INC | $592,000 | +12.1% | 32,000 | 0.0% | 0.37% | +28.3% | |
| MMX | MAVERIX METALS INC | $552,000 | +10.2% | 115,000 | 0.0% | 0.35% | +25.8% | |
| PAAS | Buy | PAN AMERN SILVER CORP | $445,000 | +9.3% | 16,300 | +98.8% | 0.28% | +24.6% |
| AG | FIRST MAJESTIC silver corp | $434,000 | +15.4% | 33,000 | 0.0% | 0.27% | +31.4% | |
| SILV | Buy | SILVERCREST METALS INC | $428,000 | +12.3% | 48,000 | +14.3% | 0.27% | +28.7% |
| BTAI | Bioxcel Therapeutics Inc | $418,000 | +2.7% | 20,000 | 0.0% | 0.26% | +17.0% | |
| MRTX | New | Mirati Therapeutics, Inc | $411,000 | – | 5,000 | +100.0% | 0.26% | – |
| EQX | EQUINOX GOLD CORP | $376,000 | +22.1% | 45,500 | 0.0% | 0.24% | +39.6% | |
| MAG | Buy | MAG SILVER CORP | $352,000 | +3.2% | 21,750 | +25.7% | 0.22% | +18.2% |
| New | Context Therapeutics Ins | $303,000 | – | 139,520 | +100.0% | 0.19% | – | |
| SNGX | Sell | Soligenix Inc. | $198,000 | -31.2% | 271,580 | -37.8% | 0.12% | -21.5% |
| ANVS | Annovis Bio Inc | $190,000 | -24.0% | 14,210 | 0.0% | 0.12% | -13.1% | |
| ORMP | New | Oramed Pharmaceuticals Inc | $173,000 | – | 20,000 | +100.0% | 0.11% | – |
| ANGN | Angion BioMedica Corp | $127,000 | -27.0% | 60,000 | 0.0% | 0.08% | -16.7% | |
| AGTC | Applied Genetic Technologies | $107,000 | -43.7% | 100,000 | 0.0% | 0.07% | -35.6% | |
| KL | Exit | KIRKLAND LAKE GOLD LTD | $0 | – | -10,750 | -100.0% | -0.25% | – |
| Exit | Anavex Life Sciemves Corp | $0 | – | -210,789 | -100.0% | -2.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Aldeyra Therapeutics Inc | 35 | Q3 2023 | 31.6% |
| Corbus Pharmaceuticals HLDGS | 30 | Q3 2022 | 46.5% |
| Abeona Therapeutics Inc | 30 | Q3 2022 | 34.8% |
| Biohaven Pharmactl Hldg Co L | 26 | Q3 2023 | 79.6% |
| Entera Bio Ltd | 22 | Q3 2023 | 7.8% |
| Ampio Pharmaceuticals Inc. | 21 | Q2 2018 | 11.0% |
| Soligenix Inc. | 20 | Q3 2022 | 1.7% |
| Eiger Biopharmaceuticals Inc | 19 | Q3 2022 | 5.8% |
| Applied Therapeutics Inc | 18 | Q3 2023 | 19.7% |
| Alcobra Ltd | 18 | Q3 2017 | 6.5% |
View Knoll Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| HOOKIPA Pharma Inc. | June 20, 2023 | 5,517,385 | 6.8% |
| Applied Therapeutics Inc. | January 23, 2023 | 3,450,000 | 7.2% |
| Orgenesis Inc. | August 14, 2020 | 1,316,364 | 5.9% |
| Corbus Pharmaceuticals Holdings, Inc. | February 14, 2020 | 5,045,870 | 7.1% |
| ABEONA THERAPEUTICS INC. | February 14, 2018 | 2,359,767 | 5.0% |
| SOLIGENIX, INC. | November 13, 2017 | 870,000 | 9.9% |
| ABEONA THERAPEUTICS INC. | February 14, 2017 | 2,359,767 | 5.9% |
| ALCOBRA LTD. | February 14, 2017 | 1,205,498 | 4.4% |
| Ampio Pharmaceuticals, Inc. | February 14, 2017 | 2,738,322 | 4.8% |
| RITTER PHARMACEUTICALS INC | February 14, 2017 | 952,434 | 8.2% |
View Knoll Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-01-16 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-04 |
| 13F-HR | 2023-08-15 |
| SC 13G | 2023-06-20 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-01-23 |
| 13F-HR | 2022-11-14 |
View Knoll Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.